Cargando…

Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients

Myelodysplastic syndrome is a bone marrow failure in which differentiation and maturity do not happen naturally and dysplasia exists in each of 3 cell categories in Bone marrow. Refractory anemia is one of the major complaints with which the patients come to hematology clinics, which in diagnostic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Aznab, Mozaffar, Kavianymoghadam, Kaveh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913137/
https://www.ncbi.nlm.nih.gov/pubmed/24505525
_version_ 1782302183457292288
author Aznab, Mozaffar
Kavianymoghadam, Kaveh
author_facet Aznab, Mozaffar
Kavianymoghadam, Kaveh
author_sort Aznab, Mozaffar
collection PubMed
description Myelodysplastic syndrome is a bone marrow failure in which differentiation and maturity do not happen naturally and dysplasia exists in each of 3 cell categories in Bone marrow. Refractory anemia is one of the major complaints with which the patients come to hematology clinics, which in diagnostic considerations lead to MDS as diagnosis. Often there is no recognized reason for this, so it is called “primary MDS”. In practice, we meet some patients who have MDS criteria however we can also find specific reasons for it; therefore we call it “secondary MDS”. One of the most important reasons for secondary MDS is the side effects of medications used in chemotherapy and radiotherapy in patients who undergo these therapies. We observed 6 patients in this case study during lengthy follow up that were diagnosed as MDS and during follow up period malignancy appeared in 6 cases. Supportive and therapeutic measures in these patients did not considerably improve blood cell count, most patients required blood injection and antibiotics for infection treatment. However align with malignancy treatment such problems are completely resolved both in terms of clinical and laboratory.
format Online
Article
Text
id pubmed-3913137
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-39131372014-02-06 Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients Aznab, Mozaffar Kavianymoghadam, Kaveh Int J Hematol Oncol Stem Cell Res Case Series Myelodysplastic syndrome is a bone marrow failure in which differentiation and maturity do not happen naturally and dysplasia exists in each of 3 cell categories in Bone marrow. Refractory anemia is one of the major complaints with which the patients come to hematology clinics, which in diagnostic considerations lead to MDS as diagnosis. Often there is no recognized reason for this, so it is called “primary MDS”. In practice, we meet some patients who have MDS criteria however we can also find specific reasons for it; therefore we call it “secondary MDS”. One of the most important reasons for secondary MDS is the side effects of medications used in chemotherapy and radiotherapy in patients who undergo these therapies. We observed 6 patients in this case study during lengthy follow up that were diagnosed as MDS and during follow up period malignancy appeared in 6 cases. Supportive and therapeutic measures in these patients did not considerably improve blood cell count, most patients required blood injection and antibiotics for infection treatment. However align with malignancy treatment such problems are completely resolved both in terms of clinical and laboratory. Tehran University of Medical Sciences 2013 /pmc/articles/PMC3913137/ /pubmed/24505525 Text en © 2013 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Case Series
Aznab, Mozaffar
Kavianymoghadam, Kaveh
Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients
title Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients
title_full Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients
title_fullStr Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients
title_full_unstemmed Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients
title_short Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients
title_sort secondary myelodysplastic syndrome may happen same as paraneoplastic syndrome in a period of time and prior to the appearance of malignancy: a case study of 6 patients
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913137/
https://www.ncbi.nlm.nih.gov/pubmed/24505525
work_keys_str_mv AT aznabmozaffar secondarymyelodysplasticsyndromemayhappensameasparaneoplasticsyndromeinaperiodoftimeandpriortotheappearanceofmalignancyacasestudyof6patients
AT kavianymoghadamkaveh secondarymyelodysplasticsyndromemayhappensameasparaneoplasticsyndromeinaperiodoftimeandpriortotheappearanceofmalignancyacasestudyof6patients